{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T14:01:12Z","timestamp":1774101672078,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,21]]},"DOI":"10.7759\/cureus.105594","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:18:22Z","timestamp":1774099102000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Familial Chylomicronemia Syndrome With Refractory Hypertriglyceridemia and Multisystem Complications Managed With Chronic Plasmapheresis and Olezarsen: A Case Report"],"prefix":"10.7759","author":[{"given":"Christopher  M","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rae-Anne","family":"Kastle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hima","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira R","family":"Haberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriana","family":"Youkhana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass A","year":"2020","unstructured":"Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020, 287:340-8. 10.1111\/joim.13016","journal-title":"J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele RA","year":"2025","unstructured":"Hegele RA, Ahmad Z, Ashraf A, et al.. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. J Clin Lipidol. 2025, 19:83-94. 10.1016\/j.jacl.2024.09.008","journal-title":"J Clin Lipidol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association","volume":"19","author":"Javed F","year":"2025","unstructured":"Javed F, Hegele RA, Garg A, et al.. Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association. J Clin Lipidol. 2025, 19:382-403. 10.1016\/j.jacl.2025.03.013","journal-title":"J Clin Lipidol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-022-01768-x","article-title":"Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study","volume":"22","author":"Rodriguez FH","year":"2023","unstructured":"Rodriguez FH, Estrada JM, Quintero HM, Nogueira JP, Porras-Hurtado GL. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study. Lipids Health Dis. 2023, 22:43. 10.1186\/s12944-022-01768-x","journal-title":"Lipids Health Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101365","article-title":"Pathogenicity assessment of genetic variants identified in patients with severe hypertriglyceridemia: novel cases of familial chylomicronemia syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society","volume":"27","author":"Ariza MJ","year":"2025","unstructured":"Ariza MJ, Coca-Prieto I, Rioja J, et al.. Pathogenicity assessment of genetic variants identified in patients with severe hypertriglyceridemia: novel cases of familial chylomicronemia syndrome from the Dyslipidemia Registry of the Spanish Atherosclerosis Society. Genet Med. 2025, 27:101365. 10.1016\/j.gim.2025.101365","journal-title":"Genet Med"},{"key":"ref6","unstructured":"FDA approves drug to reduce triglycerides in adult patients with familial chylomicronemia syndrome. (2024). Accessed. March 14, 2026: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chyl...."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000436438.60145.5a","article-title":"Issues in hypertriglyceridemic pancreatitis: an update","volume":"48","author":"Scherer J","year":"2014","unstructured":"Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014, 48:195-203. 10.1097\/01.mcg.0000436438.60145.5a","journal-title":"J Clin Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i42.7276","article-title":"Diagnosis and treatment of diabetes mellitus in chronic pancreatitis","volume":"19","author":"Ewald N","year":"2013","unstructured":"Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol. 2013, 19:7276-81. 10.3748\/wjg.v19.i42.7276","journal-title":"World J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200411000-00010","article-title":"Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis","volume":"328","author":"Iskandar SB","year":"2004","unstructured":"Iskandar SB, Olive KE. Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci. 2004, 328:290-4. 10.1097\/00000441-200411000-00010","journal-title":"Am J Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(12)80135-1","article-title":"Therapeutic plasma exchange: complications and management","volume":"23","author":"Mokrzycki MH","year":"1994","unstructured":"Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994, 23:817-27. 10.1016\/s0272-6386(12)80135-1","journal-title":"Am J Kidney Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s44337-025-00329-2","article-title":"Efficacy and safety of olezarsen in treating hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Saddique MN","year":"2025","unstructured":"Saddique MN, Thapa R, Khan Y, et al.. Efficacy and safety of olezarsen in treating hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials. Discov Med. 2025, 2:117. 10.1007\/s44337-025-00329-2","journal-title":"Discov Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-022-01649-3","article-title":"RNA-based therapy in the management of lipid disorders: a review","volume":"21","author":"Blom DJ","year":"2022","unstructured":"Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 2022, 21:41. 10.1186\/s12944-022-01649-3","journal-title":"Lipids Health Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi EM","year":"2008","unstructured":"Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008, 114:611-24. 10.1042\/CS20070308","journal-title":"Clin Sci (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet D","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, et al.. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015, 373:438-47. 10.1056\/NEJMoa1400283","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.03.007","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial","volume":"17","author":"Witztum JL","year":"2023","unstructured":"Witztum JL, Gaudet D, Arca M, et al.. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: long-term efficacy and safety data from patients in an open-label extension trial. J Clin Lipidol. 2023, 17:342-55. 10.1016\/j.jacl.2023.03.007","journal-title":"J Clin Lipidol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes ES","year":"2024","unstructured":"Stroes ES, Alexander VJ, Karwatowska-Prokopczuk E, et al.. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024, 390:1781-92. 10.1056\/NEJMoa2400201","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251332500","article-title":"Olezarsen for the treatment of familial chylomicronemia syndrome","volume":"59","author":"Phillips B","year":"2025","unstructured":"Phillips B, Abbott C, Breit S, St Onge E. Olezarsen for the treatment of familial chylomicronemia syndrome. Ann Pharmacother. 2025, 59:1031-6. 10.1177\/10600280251332500","journal-title":"Ann Pharmacother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000667","article-title":"Metabolic syndrome and major depression","volume":"19","author":"Marazziti D","year":"2014","unstructured":"Marazziti D, Rutigliano G, Baroni S, Landi P, Dell'Osso L. Metabolic syndrome and major depression. CNS Spectr. 2014, 19:293-304. 10.1017\/S1092852913000667","journal-title":"CNS Spectr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471295-severe-familial-chylomicronemia-syndrome-with-refractory-hypertriglyceridemia-and-multisystem-complications-managed-with-chronic-plasmapheresis-and-olezarsen-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:18:23Z","timestamp":1774099103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471295-severe-familial-chylomicronemia-syndrome-with-refractory-hypertriglyceridemia-and-multisystem-complications-managed-with-chronic-plasmapheresis-and-olezarsen-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.105594","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,21]]}}}